关键词：癌症免疫疗法；增强；免疫系统；内在能力；成功抗癌；副作用少；显著增长
摘 要：Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market. The global cancer immunotherapies market is growing significantly and will post a CAGR of 15.17% during the forecast period. In 2015, the Americas was the major market contributor, followed by EMEA. However, the market in APAC has major opportunities for growth, which can increase the region's revenue contribution to the global market.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Overview of cancer immunotherapies

Epidemiology

Spending on cancer

Cost of cancer treatment

Reimbursement policies

Economic burden of cancer

Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio

Anticipated number of products with single and multiindications

by 2020

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by type

Cancer monoclonal antibodies

Clinical trials of cancer monoclonal antibodies

Immune checkpoint inhibitors

Cancer vaccines

Non-specific immunotherapies

Global cancer monoclonal antibodies market

Global cancer vaccines market

Global immune checkpoint inhibitors market

Global non-specific immunotherapies market

PART 09: Geographical segmentation

Global cancer immunotherapies market by geography

2015-2020

Cancer immunotherapies market in Americas

Cancer immunotherapies market in EMEA

Cancer immunotherapies market in APAC

PART 10: Market drivers

Increase in prevalence of cancers

Increase in demand for cancer monoclonal antibodies

Patient assistance programs

Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges

Patent expiry of top-selling drugs

Poor diagnosis and screening

High developmental costs

Risk of side-effects

Stringent regulations

PART 13: Impact of drivers and challenges

PART 14: Market trends

Increase in cancer awareness

Emergence of targeted and combination therapies

Emergence of biosimilars

Strategic alliances

PART 15: Vendor landscape

Competitive scenario

Market share analysis 2015

Amgen

Bristol-Myers Squibb

F. Hoffmann-La Roche

GlaxoSmithKline

Merck

Takeda Pharmaceuticals

Other prominent vendors

PART 16: Appendix

List of abbreviations

PART 17: Explore Technavio